Title:
INFLUENZA VACCINE
Document Type and Number:
WIPO Patent Application WO/2022/210763
Kind Code:
A1
Abstract:
The present invention provides an influenza vaccine that has high immunogenicity in children and elderly people and that is highly effective in comparison with conventional split vaccines. Provided is an influenza vaccine composition to be administered to children and/or elderly people, said composition containing, as viral antigens, inactivated whole virions that have been subjected to an inactivation process with β-propiolactone.
Inventors:
MITSUMATA RYOTARO (JP)
NARAHARA TOMOHIRO (JP)
NARAHARA TOMOHIRO (JP)
Application Number:
PCT/JP2022/015638
Publication Date:
October 06, 2022
Filing Date:
March 29, 2022
Export Citation:
Assignee:
DENKA COMPANY LTD (JP)
International Classes:
A61K39/145; A61K39/00; A61P31/16
Domestic Patent References:
| WO2021045073A1 | 2021-03-11 |
Other References:
SABBAGHI AILAR, MIRI SEYED MOHAMMAD, KESHAVARZ MOHSEN, ZARGAR MOHSEN, GHAEMI AMIR: "Inactivation methods for whole influenza vaccine production", REVIEWS IN MEDICAL VIROLOGY, CHICHESTER, GB, vol. 29, no. 6, 1 November 2019 (2019-11-01), GB , XP055799025, ISSN: 1052-9276, DOI: 10.1002/rmv.2074
THEONE C. KON, ADRIAN ONU, LAURENTIU BERBECILA, EMILIA LUPULESCU, ALINA GHIORGISOR, GIDEON F. KERSTEN, YI-QING CUI, JEAN-PIERRE AM: "Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes", PLOS ONE, vol. 11, no. 3, pages e0150700, XP055375120, DOI: 10.1371/journal.pone.0150700
CHU KAI; XU KANGWEI; TANG RONG; TIAN XIAOHUI; HU JIALEI; YANG TUANTUAN; LI CHANGGUI; HU YUEMEI; ZENG GANG: "Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 38, no. 37, 27 July 2020 (2020-07-27), AMSTERDAM, NL , pages 5940 - 5946, XP086235930, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2020.06.071
VASSELON TDETMERS PA: "Toll receptors: a central element in innate immune responses", INFECT IMMUN., vol. 70, no. 3, March 2002 (2002-03-01), pages 1033 - 41
RENSHAW MROCKWELL JENGLEMAN CGEWIRTZ AKATZ JSAMBHARA S: "Cutting edge: impaired Toll-like receptor expression and function in aging", J IMMUNOL., vol. 169, no. 9, 1 November 2002 (2002-11-01), pages 4697 - 701
AKIRA S: "Innate immunity and adjuvants", PHILOS TRANS R SOC LOND B BIOL SCI., vol. 366, no. 1579, 12 October 2011 (2011-10-12), pages 2748 - 55
THEONE C. KON, ADRIAN ONU, LAURENTIU BERBECILA, EMILIA LUPULESCU, ALINA GHIORGISOR, GIDEON F. KERSTEN, YI-QING CUI, JEAN-PIERRE AM: "Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes", PLOS ONE, vol. 11, no. 3, pages e0150700, XP055375120, DOI: 10.1371/journal.pone.0150700
CHU KAI; XU KANGWEI; TANG RONG; TIAN XIAOHUI; HU JIALEI; YANG TUANTUAN; LI CHANGGUI; HU YUEMEI; ZENG GANG: "Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 38, no. 37, 27 July 2020 (2020-07-27), AMSTERDAM, NL , pages 5940 - 5946, XP086235930, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2020.06.071
VASSELON TDETMERS PA: "Toll receptors: a central element in innate immune responses", INFECT IMMUN., vol. 70, no. 3, March 2002 (2002-03-01), pages 1033 - 41
RENSHAW MROCKWELL JENGLEMAN CGEWIRTZ AKATZ JSAMBHARA S: "Cutting edge: impaired Toll-like receptor expression and function in aging", J IMMUNOL., vol. 169, no. 9, 1 November 2002 (2002-11-01), pages 4697 - 701
AKIRA S: "Innate immunity and adjuvants", PHILOS TRANS R SOC LOND B BIOL SCI., vol. 366, no. 1579, 12 October 2011 (2011-10-12), pages 2748 - 55
Attorney, Agent or Firm:
THE PATENT CORPORATE BODY ARUGA PATENT OFFICE (JP)
Download PDF:
Previous Patent: ILLUMINATOR IN VEHICLE INTERIOR
Next Patent: INFLUENZA VACCINE FOR TRANSNASAL ADMINISTRATION
Next Patent: INFLUENZA VACCINE FOR TRANSNASAL ADMINISTRATION